ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by ResMed (RMD)
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
RMD STOCK ALERT: Levi & Korsinsky Notifies ResMed Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities Laws - RMD
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed: Potentially Undervalued Amid Increasing Sleep Apnea Awareness
ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS growth at 12.5% annually with a P/E of 25 gives a 2034 price target of $529.25 and an implied 10.9% CAGR, with potential for higher returns. Risks include competitive pressures from Philips' market re-entry, technological advances reducing OSA prevalence, and challenges in increasing diagnosis rates, yet ResMed's strong market position supports long-term investment.
4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR
Stocks such as ResMed (RMD), Badger Meter (BMI), Leidos (LDOS) and Ingersoll Rand (IR) are currently exhibiting superb earnings growth.
ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be.
Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.
Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling
Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have an impact on ResMed's future business.
Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea
Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea.
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.
